Recent advances in gene therapy of endometriosis

Recent Patents on DNA and Gene Sequences

Volumn 7, Issue 3, 2013, Pages 169-178

  Shubina, Anastasia N ^a   Egorova, Anna A ^a   Baranov, Vladislav S ^a   Kiselev, Anton V ^a  

^a D O OTT RESEARCH INSTITUTE OF OBSTETRICS   (Russian Federation)

Author keywords

Angiogenesis; Endometriosis; Gene delivery; Gene therapy; Inflammation

Indexed keywords

ANATOMY; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ENDOMETRIOSIS; ENDOMETRIUM CELL; ENVIRONMENTAL FACTOR; EPIGENETICS; FERTILITY; GENE THERAPY; HEREDITY; HORMONAL THERAPY; HUMAN; IMMUNE SYSTEM; IMMUNOTHERAPY; INFERTILITY THERAPY; NERVOUS SYSTEM DEVELOPMENT; PAIN; PATHOGENESIS; PERITONEAL FLUID; PRIORITY JOURNAL; REVIEW; SUICIDE GENE THERAPY; VASCULARIZATION; VIROTHERAPY;

ARYL HYDROCARBON HYDROXYLASES; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; ENDOMETRIOSIS; FEMALE; GENETIC THERAPY; HOMEODOMAIN PROTEINS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PATENTS AS TOPIC; RNA INTERFERENCE;

EID: 84894103252     PISSN: 18722156     EISSN: None     Source Type: Journal    
DOI: 10.2174/18722156113079990021     Document Type: Review

References (129)

1. Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995; 270: 475-480.
2. Touchefeu Y, Harrington KJ, Galmiche JP, Vassaux G. Gene therapy, recent developments and future prospects in gastrointestinal oncology: review article. Aliment Pharmacol Ther 2010; 32: 953-968.
3. Young LS, Searle PF, Onion D, Mautner V. Viral gene therapy strategies: from basic science to clinical application. J Pathol 2006; 208: 299-318.
4. Elsabahy M, Nazarali A, Foldvari M. Non-viral nucleic acid delivery: key challenges and future directions. Curr Drug Deliv 2011; 8: 235-244.
5. The Journal of Gene Medicine. Gene Therapy Clinical Trials Worldwide. Available at: http://www.wiley.com//legacy/wileychi/ genmed/clinical/ (Accessed on: December 30, 2012).
6. Kanerva A, Raki M, Hemminki A. Gene therapy of gynaecological diseases. Expert Opin Biol Ther 2007; 8: 1347-1361.
7. Hassan MH, Othman EE, Hornung D, Al-Hendy A. Gene therapy of benign gynecological diseases. Adv Drug Deliv Rev 2009; 61: 822-835.
8. Lebovic DI, Mueller MD, Taylor RN. Immunobiology of endometriosis. Fertil Steril 2001; 75: 1-10.
9. Baldi A, Campioni M, Signorile PG. Endometriosis: pathogenesis, diagnosis, therapy and association with cancer (review). Oncol Rep 2008; 19: 843-846.
10. Kyama CM, Debrock S, Mwenda JM, D'Hooghe TM. Potential involvement of the immune system in the development of endometriosis. Reprod Biol Endocrinol 2003; 1: 123.
11. Tariverdian N, Theoharides TC, Siedentopf F, et al. Neuroendocrine-immune disequilibrium and endometriosis: an interdisciplinary approach. Semin Immunopathol 2007; 29: 193-210.
12. Gazvani R, Templeton A. New considerations for the pathogenesis of endometriosis. Int J Gynaecol Obstet 2002; 76: 117-126.
13. Rahmioglu N, Missmer SA, Montgomery GW, Zondervan KT. Insights into Assessing the Genetics of Endometriosis. Curr Obstet Gynecol Rep 2012; 1: 124-137.
14. Rizner TL. Estrogen metabolism and action in endometriosis. Mol Cell Endocrinol 2009; 307: 8-18.
15. Castagnetta LA, Lo Casto M, Granata OM. Estrogen content and metabolism in human breast tumor tissues and cells. Ann N Y Acad Sci 1996; 784: 314-321.
16. Sasaki M, Dharia A, Oh BR, Tanaka Y, Fujimoto S, Dahiya R. Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer. Cancer Res 2001; 1: 97-102.
17. Bulun SE, Cheng YH, Yin P, et al. Progesterone resistance in endometriosis: Link to failure to metabolize estradiol. Mol Cell Endocrinol 2006; 2: 94-103.
18. Melioli G, Semino C, Semino A, Venturini PL, Ragni N. Recombinant interleukin-2 corrects in vitro the immunological defect of endometriosis. Am J Reprod Immunol 1993; 30: 218-227.
19. Pizzo A, Salmeri FM, Ardita FV, Sofo V, Tripepi M, Marsico S. Behaviour of cytokine levels in serum and peritoneal fluid of women with endometriosis. Gynecol Obstet Invest 2002; 54: 82-87.
20. Buchweitz O, Staebler A, Wülfing P, Hauzman E, Greb R, Kiesel L. COX-2 overexpression in peritoneal lesions is correlated with nonmenstrual chronic pelvic pain. Eur J Obstet Gynecol Reprod Biol 2006; 124: 216-221.
21. Hornung D, Bentzien F, Wallwiener D, Kiesel L, Taylor RN. Chemokine bioactivity of RANTES in endometriotic and normal endometrial stromal cells and peritoneal fluid. Mol Hum Reprod 2001; 7: 163-168.
22. McLaren J, Prentice A, Charnock-Jones DS, Smith SK. Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod 1996; 11: 220-223.
23. González-Ramos R, Donnez J, Defrère S, et al. Nuclear factorkappa B is constitutively activated in peritoneal endometriosis. Mol Hum Reprod 2007; 13: 503-509.
24. Groothuis PG, Nap AW, Winterhager E, Grümmer R. Vascular development in endometriosis. Angiogenesis 2005; 8: 147-156.
25. McLaren J. Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update 2000; 6: 45-55.
26. Oosterlynck DJ, Meuleman C, Sobis H, Vandeputte M, Koninckx PR. Angiogenic activity of peritoneal fluid from women with endometriosis. Fertil Steril 1993; 59: 778-782.
27. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246: 1309-1312.
28. Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986; 46: 5629-5632.
29. Taylor RN, Yu J, Torres PB, et al. Mechanistic and therapeutic implications of angiogenesis in endometriosis. Reprod Sci 2009; 16: 140-146.
30. Kalka C, Masuda H, Takahashi T, et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 2000; 86: 1198-1202.
31. Fontaine V, Filipe C, Werner N, et al. Essential role of bone marrow fibroblast growth factor-2 in the effect of estradiol on reendothelialization and endothelial progenitor cell mobilization. Am J Pathol 2006; 169: 1855-1862.
32. Strehlow K, Werner N, Berweiler J, et al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 2003; 107: 3059-3065.
33. De Leon FD, Vijayakumar R, Brown M, Rao CV, Yussman MA, Schultz G. Peritoneal fluid volume, estrogen, progesterone, prostaglandin, and epidermal growth factor concentrations in patients with and without endometriosis. Obstet Gynecol 1986; 68: 189-194.
34. Asante A, Taylor RN. Endometriosis: the role of neuroangiogenesis. Annu Rev Physiol 2011; 73: 163-182.
35. Browne AS, Yu J, Huang RP, Francisco AM, Sidell N, Taylor RN. Proteomic identification of neurotrophins in the eutopic endometrium of women with endometriosis. Fertil Steril 2012; 98: 713-719.
36. Weinstein BM. Vessels and nerves: marching to the same tune. Cell 2005; 120: 299-302.
37. Kao LC, Germeyer A, Tulac S, et al. Expression profiling of endometrium from women with endometriosis reveals candidate genes for disease-based implantation failure and infertility. Endocrinology 2003; 144: 2870-2881.
38. Shen F, Liu X, Geng JG, Guo SW. Increased immunoreactivity to SLIT/ROBO1 in ovarian endometriomas: a likely constituent biomarker for recurrence. Am J Pathol 2009; 175: 479-488.
39. Tamburro S, Canis M, Albuisson E, Dechelotte P, Darcha C, Mage G. Expression of transforming growth factorβ1 in nerve fibers is related to dysmenorrhea and laparoscopic appearance of endometriotic implants. Fertil Steril 2003; 80: 1131-1136.
40. Anaf V, Simon P, El Nakadi I, et al. Hyperalgesia, nerve infiltration and nerve growth factor expression in deep adenomyotic nodules, peritoneal and ovarian endometriosis. Hum Reprod 2002; 17: 1895-900.
41. Tokushige N, Markham R, Russell P, Fraser IS. Different types of small nerve fibers in eutopic endometrium and myometrium in women with endometriosis. Fertil Steril 2007; 88: 795-803.
42. Tokushige N, Markham R, Russell P, Fraser IS. High density of small nerve fibres in the functional layer of the endometrium in women with endometriosis. Hum Reprod 2006; 21: 782-787.
43. Mechsner S, Schwarz J, Thode J, Loddenkemper C, Salomon DS, Ebert AD. Growth-associated protein 43-positive sensory nerve fibers accompanied by immature vessels are located in or near peritoneal endometriotic lesions. Fertil Steril 2007; 88: 581-587.
44. Kennedy S. The genetics of endometriosis. J Reprod Med 1998; 43: 263-268.
45. Zondervan KT, Cardon LR, Kennedy SH. The genetic basis of endometriosis. Curr Opin Obstet Gynecol 2001; 13: 309-314.
46. Treloar SA, Wicks J, Nyholt DR, et al. Genomewide linkage study in 1,176 affected sister pair families identifies a significant suscep tibility locus for endometriosis on chromosome 10q26. Am J Hum Genet 2005; 77: 365-376.
47. Painter JN, Anderson CA, Nyholt DR, et al. Genome-wide association study identifies a locus at 7p15.2 associated with endometriosis. Nat Genet 2011; 43: 51-54.
48. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology 2003; 144: 3382-3398.
49. Uno S, Zembutsu H, Hirasawa A, et al. A genome-wide association study identifies genetic variants in the CDKN2BAS locus associated with endometriosis in Japanese. Nat Genet 2010; 42: 707-710.
50. Jarinova O, Stewart AF, Roberts R, et al. Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler Thromb Vasc Biol 2009; 29: 1671-1677.
51. Liu Y, Sanoff HK, Cho H, et al. INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. PLoS One 2009; 4: e5027.
52. Pasmant E, Laurendeau I, Héron D, Vidaud M, Vidaud D, Bièche I. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res 2007; 67: 3963-3969.
53. Vainio S, Heikkilä M, Kispert A, Chin N, McMahon AP. Female development in mammals is regulated by Wnt-4 signalling. Nature 1999; 397: 405-409.
54. Boyer A, Lapointe E, Zheng X, et al. WNT4 is required for normal ovarian follicle development and female fertility. FASEB J 2010; 24: 3010-3025.
55. Rosser MD, Parvez IH, Dyan NA, Justin CK. The emerging role of epigenetics and miRNAs in endometriosis. Expert Review of Obstretrics and Gynecology 2011; 6: 431-450.
56. Wu Y, Strawn E, Basir Z, Halverson G, Guo SW. Aberrant expression of deoxyribonucleic acid methyltransferases DNMT1, DNMT3A, and DNMT3B in women with endometriosis. Fertil Steril 2007; 87: 24-32.
57. Kim JJ, Taylor HS, Lu Z, et al. Altered expression of HOXA10 in endometriosis: potential role in decidualization. Mol Hum Reprod 2007; 13: 323-332.
58. Wu Y, Halverson G, Basir Z, Strawn E, Yan P, Guo SW. Aberrant methylation at HOXA10 may be responsible for its aberrant expression in the endometrium of patients with endometriosis. Am J Obstet Gynecol 2005; 193: 371-380.
59. Wu Y, Strawn E, Basir Z, Halverson G, Guo SW. Promoter hypermethylation of progesterone receptor isoform B (PR-B) in endometriosis. Epigenetics 2006; 1: 106-11.
60. Xue Q, Lin Z, Yin P, et al. Transcriptional activation of steroidogenic factor-1 by hypomethylation of the 5' CpG island in endometriosis. J Clin Endocrinol Metab 2007; 92: 3261-7.
61. Zhao ZZ, Croft L, Nyholt DR, et al. Evaluation of polymorphisms in predicted target sites for micro RNAs differentially expressed in endometriosis. Mol Hum Reprod 2011; 17: 92-103.
62. Ohlsson Teague EM, Van der Hoek KH, Van der Hoek MB, et al. MicroRNA-regulated pathways associated with endometriosis. Mol Endocrinol 2009; 23: 265-75.
63. Pan Q, Luo X, Toloubeydokhti T, Chegini N. The expression profile of micro-RNA in endometrium and endometriosis and the influence of ovarian steroids on their expression. Mol Hum Reprod 2007; 13: 797-806.
64. Sonkoly E, Stahle M, Pivarcsi A. MicroRNAs and immunity: novel players in the regulation of normal immune function and inflammation. Semin Cancer Biol 2008; 18: 131-140.
65. Toloubeydokhti T, Pan Q, Luo X, Bukulmez O, Chegini N. The expression and ovarian steroid regulation of endometrial micro-RNAs. Reprod Sci 2008; 15: 993-1001.
66. Wickramasinghe NS, Manavalan TT, Dougherty SM, Riggs KA, Li Y, Klinge CM. Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res 2009; 37: 2584-95.
67. Nothnick WB. Endometriosis: in search of optimal treatment. Minerva Ginecol 2010; 62: 17-31.
68. Othman EE, Salama S, Ismail N, Al-Hendy A. Toward gene therapy of endometriosis: adenovirus-mediated delivery of dominant negative estrogen receptor genes inhibits cell proliferation, reduces cytokine production, and induces apoptosis of endometriotic cells. Fertil Steril 2007; 88: 462-471.
69. Ince BA, Zhuang Y, Wrenn CK, Shapiro DJ, Katzenellenbogen BS. Powerful dominant negative mutants of the human estrogen receptor. J Biol Chem 1993; 268: 14026-32.
70. LaBarbera AR, Wang YF, Zhu HZ. Antisense oligonucleotides for fertility and menstrual cycle regulation and for chemopreventive and chemotherapeutic use. US7273932, 2007.
71. Hsu SY, Hsueh JW. Mammalian relaxin receptors. US20090298770, 2009.
72. Palejwala S, Tseng L, Wojtczuk A, Weiss G, Goldsmith LT. Relaxin gene and protein expression and its regulation of procollagenase and vascular endothelial growth factor in human endometrial cells. Biol Reprod 2002; 66: 1743-8.
73. Goldsmith LT, Weiss G, Palejwala S, et al. Relaxin regulation of endometrial structure and function in the rhesus monkey. Proc Natl Acad Sci U S A 2004; 101: 4685-9.
74. Morelli SS, Petraglia F, Weiss G, et al. Endometrial expression of relaxin and relaxin receptor in endometriosis. Fertil Steril 2010; 94: 2885-7.
75. Becker CM, Rohwer N, Funakoshi T, et al. 2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis. Am J Pathol 2008; 172: 534-44.
76. Becker CM, Wright RD, Satchi-Fainaro R, et al. A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy. Am J Pathol 2006; 168: 2074-84.
77. Nap AW, Griffioen AW, Dunselman GA, et al. Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab 2004; 89: 1089-95.
78. Hull ML, Charnock-Jones DS, Chan CL, et al. Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab 2003; 88: 2889-99.
79. Becker CM, Sampson DA, Rupnick MA, et al. Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril 2005; 84: 1144-55.
80. Pauli SA, Tang H, Wang J, et al. The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent. Endocrinology 2005; 146: 1301-11.
81. Dabrosin C, Gyorffy S, Margetts P, Ross C, Gauldie J. Therapeutic effect of angiostatin gene transfer in a murine model of endometriosis. Am J Pathol 2002; 161: 909-18.
82. Zhao MD, Sun YM, Fu GF, et al. Gene therapy of endometriosis introduced by polymeric micelles with glycolipid-like structure. Biomaterials 2012; 33: 634-43.
83. Dass CR, Contreras KG, Dunstan DE, Choong PF. Chitosan microparticles encapsulating PEDF plasmid demonstrate efficacy in an orthotopic metastatic model of osteosarcoma. Biomaterials 2007; 28: 3026-3033.
84. Sun Y, Che X, Zhu L, et al. Pigment epithelium derived factor inhibits the growth of human endometrial implants in nude mice and of ovarian endometriotic stromal cells in vitro. PLoS One 2012; 7: e45223.
85. Folkman J, Javaherian K, Becker K, D'Amato R. Anti-angiogenic peptides for treating or preventing endometriosis. US7645735, 2010.
86. Detmar M, JVacanti JP, Streit M, Stephen AE. Delivery of thrombospondin from implantable tissue matrices. US20020022592, 2002.
87. Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor. WO9715662, 1997.
88. Jellinek D, Green LS, Bell C, Janjić N. Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor. Biochemistry 1994; 33: 10450-6.
89. Rockwell P, Goldstein N. Monoclonal antibodies specific to VEGF receptors and uses thereof. WO9521868, 1995.
90. Robinson G. Antisense oligonucleotide inhibition of vascular endothelial growth factor expression. WO9504142, 1995.
91. Lockridge J, Pavco P, Gordon G. Method and reagent for the modulation of female reproductive diseases and conditions. US20030216335, 2003.
92. Pavco P, Lockridge J, McSwiggen J. Nucleic acid-based modulation of female reproductive diseases and conditions. US20040220128, 2004.
93. Lockridge J, Pavco P. Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway. US20040142895, 2004.
94. LeCouter J, Kowalski J, Foster J, et al. Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 2001; 412: 877-84.
95. LeCouter J, Lin R, Tejada M, et al. The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: Localization of Bv8 receptors to endothelial cells. Proc Natl Acad Sci USA 2003; 100: 2685-90.
96. Napoleone F, Watanabe C, Wood W. EV-VEGF nucleic acids and polypeptides and methods of use. WO02000711, 2002.
97. Jabbour HN, Millar RP. Treatment of endometriosis. US7615210, 2009.
98. Chandrasekharan UM, Waitkus M, Kinney CM, Walters-Stewart A, DiCorleto PE. Synergistic induction of mitogen-activated protein kinase phosphatase-1 by thrombin and epidermal growth factor requires vascular endothelial growth factor receptor-2. 2010; 30: 1983-9.
99. Krikun G, Schatz F, Taylor H, Lockwood CJ. Endometriosis and tissue factor. Ann N Y Acad Sci 2008; 1127: 101-5.
100. Lin M, Weng H, Wang X, Zhou B, Yu P, Wang Y. The role of tissue factor and protease-activated receptor 2 in endometriosis. Am J Reprod Immunol 2012; 68: 251-7.
101. Lockwood C, Krikun G. Compositions and methods for diagnosing and treating endometriosis. US20100015160, 2010.
102. Kinch MS, Carles-Kinch K. Modulators of EphA2 and ephrinA1 for the treatment of fibrosis-related disease. US20120121582, 2012.
103. Stein E, Lane AA, Cerretti DP, et al. Eph receptors discriminate specific ligand oligomers to determine alternative signaling complexes, attachment, and assembly responses. Genes Dev 1998; 12: 667-78.
104. Kamat AA, Bischoff FZ, Dang D, et al. Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. Cancer Biol Ther 2006; 5: 1369-74.
105. Khan MA, Sengupta J, Giudice LC, et al. cDNA-based transcript analysis of autologous eutopic and ectopic endometrium of women with moderate and severe endometriosis. Journal of Endometriosis 2011; 3: 8-33.
106. Kuehl FA Jr, Egan RW. Prostaglandins, arachidonic acid, and inflammation. Science 1980; 210: 978-84.
107. Kniss DA. Antisense oligonucleotides to suppress eicosanoid formation. US5859229, 1999.
108. Schneider P, Yamamoto KK, French CK. Use of cathepsin in the diagnosis and treatment of endometriosis. US6387629, 2002.
109. Schneider PA, French CK, Yamamoto KK. Use of prothymosin in the diagnosis and treatment of endometriosis. US6753138, 2004.
110. Nakamura Y, Tsunoda T, Ohsawa R, Yoshimura S, Watanabe T. Modified MELK peptides and vaccines containing the same. WO11089921, 2011.
111. Pickard MR, Green AR, Ellis IO, et al. Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer. Breast Cancer Res 2009; 11: R60.
112. Lin ML, Park JH, Nishidate T, Nakamura Y, Katagiri T. Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a proapoptotic member of the Bcl-2 family. Breast Cancer Res 2007; 9: R17.
113. Howe DC, Pullen N, Shelton DL. Treatment of endometriosis. WO10029497, 2010.
114. Zhang G, Dmitrieva N, Liu Y, McGinty KA, Berkley KJ. Endometriosis as a neurovascular condition: estrous variations in innervation, vascularization, and growth factor content of ectopic endometrial cysts in the rat. Am J Physiol Regul Integr Comp Physiol 2008; 294: R162-71.
115. Rein DT, Schmidt T, Bauerschmitz G, et al. Treatment of endometriosis with a VEGF-targeted conditionally replicative adenovirus. Fertil Steril 2010; 93: 2687-94.
116. Paupoo AA, Zhu ZB, Wang M, Rein DT, Starzinski-Powitz A, Curiel DT. A conditionally replicative adenovirus, CRAd-S-pK7, can target endometriosis with a cell-killing effect. Hum Reprod 2010; 25: 2068-83.
117. Fortin M, Lépine M, Merlen Y, et al. Quantitative assessment of human endometriotic tissue maintenance and regression in a noninvasive mouse model of endometriosis. Mol Ther 2004; 9: 540-7.
118. Favier B, Dollé P. Developmental functions of mammalian Hox genes. Mol. Hum. Reprod 1997; 3: 115-131.
119. McGinnis W, Krumlauf R. Homeobox genes and axial patterning. Cell 1992; 68: 283-302.
120. Taylor HS, Vanden Heuvel GB, Igarashi P. A conserved Hox axis in the mouse and human female reproductive system: late establishment and persistent adult expression of the Hoxa cluster genes. Biol Reprod 1997; 57: 1338-1345.
121. Taylor HS. Endometrial gene therapy. US20020177574, 2002.
122. Nakamura Y, Ohsawa R, Konuma A. Double-stranded molecule inhibiting the expression of GPC3. WO10113507, 2010.
123. Hippo Y, Watanabe K, Watanabe A, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004; 64: 2418-23.
124. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterol 2003; 125: 89-97.
125. Maeda D, Ota S, Takazawa Y. Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol 2009; 22: 824-32.
126. Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010; 464: 1067-70.
127. Anand S, Majeti BK, Acevedo LM, et al. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med 2010; 16: 909-14.
128. Egorova A, Kiselev A, Hakli M, Ruponen M, Baranov V, Urtti A. Chemokine-derived peptides as carriers for gene delivery to CXCR4 expressing cells. J Gene Med 2009; 11: 772-81.
129. Cai L, Qiu N, Li X, et al. A novel truncated basic fibroblast growth factor fragment-conjugated poly (ethylene glycol)-cholesterol amphiphilic polymeric drug delivery system for targeting to the FGFR-overexpressing tumor cells. Int J Pharm 2011; 408: 173-82.